Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue

M J Gisycki, K L Hattotuwa, N Barnes, P K Jeffery

Background: Inhaled corticosteroids (ICS) markedly reduce bronchial mucosal inflammation in asthma but whether they have an anti-inflammatory effect in airway tissue in chronic obstructive pulmonary disease (COPD) is unknown.

Methods: A study of endobronchial biopsy samples was conducted as part of a double blind, placebo controlled, randomised trial of parallel design. Patients had mild to moderately severe COPD (FEV₁ 25–80% of predicted) and were given 3 months treatment with ICS, fluticasone propionate (FP; 500 µg twice daily, n=14) or placebo (n=10). Biopsy tissue taken at baseline and after treatment was examined by transmission electron microscopy (TEM) to count the numbers of all ultrastructurally distinct inflammatory cells.

Results: Compared with their baseline values, FP resulted in a significant decrease (on average 65%) in the numbers of mucosal mast cells (median 7.8 (range 1–33) v 2.8 (1–14), p<0.05). The reductive effect of FP held true when the post-treatment values of the placebo and FP groups were compared: 8.8 (1–24) v 2.8 (1–14) (p<0.05). Unexpectedly, there were significantly more neutrophils in the FP than in the placebo group: 4.0 (0–23) v 1.7 (0–8), respectively (p<0.05). There were no alterations to other cell types including mononuclear cells. Symptoms markedly improved in the patients treated with FP for 3 months.

Conclusion: Fluticasone propionate given for 3 months to patients with COPD has selective effects on the inflammatory cells in the bronchial mucosa: the reduction in mast cell numbers may account for the improvement in symptoms over this time.
METHODS

Patients

Patients were chosen who had clinical characteristics that closely resembled those in the ISOLDE study. They were recruited from chest clinics at the London Chest Hospital and by advertisement. The study conformed to the Declaration of Helsinki and ethical approval was obtained from the East London City Health Authority.

Patients eligible for study were aged 40–75 years, were current or ex-smokers with more than 20 pack years of smoking, non-atopic, and with an FEV1 25–80% of predicted which improved less than 15% following 400 µg inhaled salbutamol. Of the 37 patients who were recruited, four had mild airflow obstruction (FEV1 60–80% of predicted), 20 had moderate obstruction (40–60% of predicted), and 13 had severe airflow obstruction (<40% of predicted). Patients with severe concurrent medical problems, psychological impairment, those on immunosuppressive treatment, or with a chest infection during the 8 weeks before the study were excluded. Patients who were already on inhaled steroids had the drug withdrawn and had to be stable for at least 8 weeks before the first biopsy specimen was taken. All reliever medications (inhaled β2 agonist, anticholinergic agents, and theophylline) were continued as previously administered and required. All patients underwent a full physical examination, baseline pulmonary function testing (spirometry, flow-volume loop, and transfer factor), full blood count, assessment of electrolytes, liver function tests, total IgE, and RAST test to house dust mite, mixed feathers, grass pollen, cat, and dog fur.

The demographic characteristics of the patients are summarised in table 1.

Trial design

The recruited subjects had a run-in period of 8 weeks to ensure they were stable before the first bronchoscopic examination. Two weeks after the baseline biopsy specimen was taken, patients were randomised to receive either placebo or 500 µg FP twice daily via an Accuhaler for a period of 3 months. The subjects were required to keep a twice daily diary of peak flows and symptoms. At each monthly visit they had pulmonary function tests, and symptoms were recorded. At each visit a trial of 30 mg oral prednisolone for 2 weeks to determine the maximal degree of airflow obstruction reversibility; patients were considered as responders if their FEV1 improved by more than 15% and by at least 200 ml in absolute terms from their baseline value.

Bronchoscopic examination and processing of biopsy samples

Patients had their bronchoscopic examination as a hospital day case, applying the standards set by the American Thoracic Society. Following an overnight fast they were admitted to the day case unit and baseline observations were taken. All subjects then received 2.5 mg nebulised salbutamol and 600 µg atropine intramuscularly as premedication. During the bronchoscopic examination they were monitored by pulse oximetry, received lignocaine spray to the oropharynx, and 2.5–5 mg midazolam was given intravenously. 4% lignocaine was instilled via the bronchoscope to the vocal cords and 2% lignocaine was used intrabrachially. Bronchial biopsy specimens were obtained from the carinae of the second order bronchi of the right middle and lower lobes using a Pentax FB18x and Pentax x1718A cup forceps. Following bronchoscopic examination the patients were observed and discharged home with a follow up during the following 2 weeks. Two biopsy specimens per patient were prepared for examination by transmission electron microscopy (TEM) using the methods previously described. Areas of the biopsy specimen with intact surface epithelium were selected for further examination and quantification by TEM carried out at a total magnification of x2000 (H-7000, Hitachi, Japan).

Quantification

Inflammatory cells were counted in a subepithelial zone in the entire TEM section and expressed per 0.1 mm² of tissue, excluding areas with bronchial smooth muscle, mucus secreting glands, and oedema. The entire section was photographed at low magnification and the excluded areas were subtracted from the total area using image analysis (NIH Image 1.61, California, US). The numbers of lymphomononuclear cells, mast cells, neutrophils, eosinophils, plasma cells, macrophages, and fibroblasts were counted: a group of cells difficult to classify was included. The criteria for ultrastructural identification of morphologically distinct cell types were those described in our previously published papers. The frequency of clusters of free eosinophil granules (CFegs) as a marker of eosinophil cytolysis was also determined.

Statistical analysis

Statistical analyses were performed using computer software (Statview 5.0, Abacus Concepts, California). The coefficient of variation for the error of repeat measurement for each cell type was less than 5%. As the data were not all distributed normally, the Wilcoxon signed rank test was applied to examine differences between paired data and the Mann-Whitney U test for between treatment comparisons was applied to the post-treatment values. The Spearman rank correlation coefficient was used to evaluate associations between histological and clinical variables. Probability (p) values of less than 0.05 were accepted as statistically significant.

RESULTS

Patient characteristics

Of the 37 patients initially enrolled into the study, 31 completed the trial. One patient withdrew for personal reasons and one patient died of a cause unrelated to the study. Necropsy examination gave the cause of death as respiratory failure resulting from severe emphysema and pulmonary hypertension. Four further patients had to withdraw because of exacerbations of COPD. Most exacerbations requiring oral prednisolone occurred in the placebo group (p=0.02 compared with FP group). There was insufficient biopsy material to analyse on at least one occasion in seven patients, so they were excluded from ultrastructural analysis.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Placebo</th>
<th>Fluticasone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male/female</td>
<td>9/1</td>
<td>13/1</td>
</tr>
<tr>
<td>Age</td>
<td>65.5 (7)</td>
<td>65.3 (6)</td>
</tr>
<tr>
<td>FEV1 (l)</td>
<td>1.46 (0.4)</td>
<td>1.44 (0.4)</td>
</tr>
<tr>
<td>FEV1 (% predicted)</td>
<td>49.7 (13.4)</td>
<td>50.3 (12.7)</td>
</tr>
<tr>
<td>VC (l)</td>
<td>3.5 (0.9)</td>
<td>3.7 (0.7)</td>
</tr>
<tr>
<td>FEV1/VC (%)</td>
<td>53.6 (9.9)</td>
<td>49.9 (14.4)</td>
</tr>
<tr>
<td>FEV1 (FEV1/VC)</td>
<td>0.54 (0.2)</td>
<td>0.52 (0.3)</td>
</tr>
<tr>
<td>Reversibility (%)</td>
<td>7.6 (5.8)</td>
<td>6.8 (5.8)</td>
</tr>
<tr>
<td>Kco (% predicted)</td>
<td>55.0 (4.5)</td>
<td>52.0 (5.1)</td>
</tr>
<tr>
<td>Pack years</td>
<td>63.3 (36)</td>
<td>57.6 (36)</td>
</tr>
<tr>
<td>Cigarettes/ day</td>
<td>27.1 (17.0)</td>
<td>25.4 (19.0)</td>
</tr>
</tbody>
</table>

FEV1=forced expiratory volume in 1 second; VC= vital capacity; Kco=carbon monoxide transfer coefficient.
Patients were well matched for age, smoking history, and lung function (table 1).

Lung function

Data from 31 patients were available for analysis of lung function and symptoms and the results are published elsewhere. There were no significant differences in the lung function tests between the FP and placebo groups at the end of the treatment period. However, there were improvements in the scores for cough (p<0.05), sputum (p<0.05), and decreased use of reliever medication (p<0.05) after 3 months of FP compared with placebo. No significant differences were observed in breathlessness, wheezing, exercise tolerance, or general well being.

Of the 31 patients who completed the trial, 29 underwent an oral corticosteroid trial of 30 mg prednisolone and two patients were considered as responders. One of them was in the placebo group and reported worsening of symptoms during the trial period. The responder in the FP group reported improvement in all categories of symptoms during the trial. The examination of biopsy specimens from these subjects showed that their results did not significantly influence the between group differences. Placebo treatment had no effect on any of the clinical parameters.

Biopsy results

Adequate tissue was obtained in the 24 patients who completed the study. Most biopsy specimens had intact epithelium with a reticular basement membrane which appeared to be of normal thickness. Among the granulated cells, mast cells were most numerous at the baseline and were found both beneath and within the epithelium; those in the epithelium were often degranulated. Eosinophils occurred infrequently and were usually not degranulated; Clues, as an indicator of eosinophil lysis, were also sparse. In contrast to neutrophils, no apoptotic eosinophils were identified. Macrophages identified by their phagolysosomes were found occasionally in the process of engulfing apoptotic neutrophils. The numbers of ultrastructurally distinct cell types are shown in table 2.

Compared with their respective baseline values, FP treatment had no significant effects on the total number of inflammatory cells, lymphomononuclear cells, or macrophages in the airway mucosa. However, treatment with FP resulted in a 65% reduction in the numbers of mucosal mast cells (p<0.05), and this reduction was also significant when compared with the post-treatment values in the placebo group (p<0.05, fig 1). Comparison of post-treatment values showed that the FP group had statistically more neutrophils than the placebo group.

| Table 2 Median (range) bronchial inflammatory cells expressed per 0.1 mm² tissue |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                 | Placebo (n=10)                  | Fluticasone (n=14)             |
|                                 | Before treatment | After treatment | Before treatment | After treatment |
| Fibroblasts                      | 36.0 (6–74)         | 30.1 (9–69)    | 23.6 (12–64) | 20.0 (5–56)   |
| Lymphomononuclear cells         | 35 (10–145)         | 30.1 (1–182)   | 24.3 (11–196) | 30.2 (0–179)  |
| Mast cells                      | 10.8 (4–23)         | 8.8 (1–24)     | 7.8 (1–33)   | 2.8 (1–14)*   |
| Eosinophil total                | 1.8 (0–11)          | 0.0 (0–10)     | 1.1 (0–15)   | 1.2 (0–30)    |
| Eosinophil dense                | 0.7 (0–8)           | 0.0 (0–7)      | 0.8 (0–52)   | 0.9 (0–27)    |
| Eosinophil clear                | 0.0 (0–3)           | 0.0 (0–8)      | 0.0 (0–23)   | 0.0 (0–2)     |
| Cegs                            | 1.5 (0–12)          | 0.0 (0–3.6)    | 0.0 (0–38)   | 0.0 (0–5)     |
| Neutrophils                     | 3.0 (0–10)          | 1.7 (0–8)      | 3.2 (1–12)   | 4.0 (0–23)*   |
| Macrophages                     | 8.8 (3–20)          | 9.3 (1–20)     | 7.0 (3–31)   | 10.1 (0–20)   |
| Plasma cells                    | 3.9 (0–37)          | 3.6 (0–60)     | 5.0 (0–66)   | 1.8 (0–26)    |
| DTC                             | 17 (5–37)           | 15.1 (5–33)    | 15.4 (5–56)  | 15.9 (3–49)   |

Eosinophil dense=electron dense secretory granules; eosinophil clear= electron lucent secretory granules; Cegs = clusters of free eosinophil granules; DTC = difficult to classify.

*p<0.05 FP vs placebo.

Figure 1. Effect of treatment with fluticasone propionate (FP) on bronchial mast cells and neutrophils. A reduction in mast cells of approximately 65% compared with baseline values was seen. Neutrophils increased by a mean of 50%. Open triangles represent patients who responded positively to the prednisolone trial. Arrows indicate the median values.
group (p<0.05, fig 1). However, this relative increase in the FP group failed to reach significance compared with the respective within group baseline values (p=0.09). FP did not alter the sparse number of tissue eosinophils. The highest number of eosinophils was observed at baseline in the group subsequently treated with FP, and this was in a patient who responded positively to the course of oral prednisolone following the study. There was no effect of FP treatment on the subsets of eosinophils with “clear” or “dense” granules or on the numbers of Creqs as indices of eosinophil degranulation. Placebo had no significant effect on any parameter. There was no significant correlation between the results of lung function tests and inflammatory cells at baseline.

DISCUSSION
The current use and efficacy of ICS in the treatment of COPD has been debated.1722 To our knowledge this is the first published study of the anti-inflammatory potential of ICS on airway tissues in COPD. Three months of treatment with FP (500 µg bd) did not significantly alter the numbers of bronchial mononuclear cells, which are considered to be key mechanism to explain the beneficial effects of ICS on lung function, as measured by FEV1, remained unchanged. There was no effect of FP treatment on the reduction in numbers of Cfegs as indices of eosinophil degranulation. Placebo had no significant effect on any parameter. There was no significant correlation between the results of lung function tests and inflammatory cells at baseline.

The role of mast cells in the pathogenesis of COPD is unclear. Mast cells have been reported to increase in both the mucosa and submucosal glands in bronchial biopsies of smokers with chronic bronchitis.22 In lungs resected from smokers with cancer there is an increased number of mast cells in the epithelium of small airways which is greater in smokers with airflow obstruction (COPD),22 suggesting a role for mast cells in airflow limitation. In the present study the reduction in the number of mast cells was accompanied by a significant improvement in symptoms such as cough and sputum, and the patients given FP experienced fewer exacerbations. However, breathlessness, exercise tolerance and lung function, as measured by FEV1, remained unchanged.

Mast cell chymase is known to be a potent stimulator of mucous secreting glands in vitro.2324 Mast cells which accumulate close to mucous glands are positive for interleukin 6,25 a potent inducer of both mucous glycoprotein secretion and MUC2 gene expression in human bronchial organ explant cultures and bronchial epithelial cells.26 Vestbo and colleagues22 have reported a positive association between increased production of sputum and decline in lung function in a group of subjects with COPD; this decline was accelerated when compared with a group of COPD subjects without sputum production. Mucus hypersecretion is associated with increased risk of hospitalisation, morbidity and mortality, particularly in the later stages of COPD.23 The reduction in mast cell numbers, whose granular content may stimulate mucous secretion, could therefore be one mechanism to explain the beneficial effects of ICS on lung function observed during the first 3–6 months of the long term trials of ICS in COPD.12

In contrast to the effect on mast cells, our study showed that treatment with FP increased the number of mucosal neutrophils. Relatively high numbers of neutrophils have also been reported in bronchial biopsy specimens from severe asthmatics treated with high doses of inhaled or oral steroids.27 The presence of tissue neutrophils is the result of a balance between neutrophil recruitment and clearance/longevity. Steroids decrease neutrophil apoptosis in vitro and thus promote neutrophil survival.2829 While the TEM technique allowed us to identify and quantify the numbers of apoptotic cells, such cells were present too infrequently for conclusions to be drawn as to the effects of ICS. Moreover, the functional significance of the potential for steroids to reduce the clearance of neutrophils by their effect on apoptosis is unclear in vivo and requires further study.

Based on the lack of effect on sputum eosinophils, it has been argued that ICS are ineffective as anti-inflammatory agents in COPD.30 However, a preliminary report has been published of a reduction in biopsy eosinophils following treatment with ICS in patients with COPD who were hyperresponsive to histamine, indicating an asthmatic component.31 Interestingly, one of our COPD patients had evidence of airflow reversibility as he responded positively to a course of oral prednisolone; this patient had a relatively high baseline biopsy eosinophilia that was significantly reduced by ICS. We suggest that the lack of effect of ICS on eosinophils in COPD is due to the relatively low frequency of eosinophils at baseline, as evidenced in both the study by Keatings et al31 and our study, indicating that the signal is too small to show a treatment related effect.

In conclusion, our results show that ICS have selected anti-inflammatory effects in COPD, as evidenced by the reduction in airway tissue mast cells. Our results offer one possible explanation for the short term improvement in lung function following ICS given to patients with COPD.32 The hypothesised relationships between mast cells, mucus hypersecretion, and FEV1 require further investigation. It is clear that additional treatments still need to be found to target the key cells thought to be responsible for the progressive decline of lung function in patients with COPD.

ACKNOWLEDGEMENTS
The authors gratefully acknowledge the contributions made by Glaxo-SmithKline and Lung Pathology Discretionary Funds and thank Mr Andrew Rogers for technical assistance and advice.

Authors’ affiliations
M J Gazycki, K L Hattotuwa, P K J Jeffery, Lung Pathology Unit, Imperial College School of Medicine at the Royal Brompton Hospital, London, UK
K L Hattotuwa, N Barnes, London Chest Hospital, London, UK

REFERENCES
Corticosteroid treatment in COPD


Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue

M J Gizycki, K L Hattotuwa, N Barnes and P K Jeffery

Thorax 2002 57: 799-803
doi: 10.1136/thorax.57.9.799

Updated information and services can be found at:
http://thorax.bmj.com/content/57/9/799

These include:

References
This article cites 31 articles, 9 of which you can access for free at:
http://thorax.bmj.com/content/57/9/799#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Asthma (1782)
- Clinical trials (epidemiology) (557)
- Drugs: respiratory system (526)
- Inflammation (1020)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/